Overview
Now in its 44th year, the Chemotherapy Foundation Symposium (CFS®) brings together thousands of health care professionals for an exciting 3-day conference that promotes the delivery of evidence-based, state-of-the-art cancer care. Internationally renowned faculty will provide you with expert insights on the latest developments in cancer therapeutics, offering a unique opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize clinical care for your patients with cancer.
Exciting new developments and rapid changes continue to occur in the management of solid and hematologic malignancies. In the past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to do so. Optimized testing and treatments for early and advanced disease, including chemotherapeutics, targeted therapies, immunotherapies—alone and in combination—and multimodal strategies continue to improve clinical outcomes. CFS® offers you the critical knowledge you need to safely and effectively integrate these strategies into your practice.
System requirements for virtual attendees are available here.
Learning Objectives
Upon completion of this activity, learners will be better able to:
- Describe the supporting evidence for novel biomarker-testing approaches that guide the use of targeted therapies and/or modification of treatment plans
- Evaluate efficacy and safety data from recent pivotal trials investigating new and emerging therapies
- Develop personalized treatment plans based on evolving evidence, guideline recommendations, and individual patient/disease characteristics
- Apply strategies to identify and mitigate treatment-related adverse effects associated with novel therapies and combination regimens
Target Audience
This educational activity is intended for oncologists, hematologists, nurses, advanced practice providers, pharmacists, radiotherapists, immunologists, fellows, researchers, pathologists, and other healthcare professionals involved in or interested in the treatment and management of patients with cancer, including solid tumors and hematologic malignancies.
Benjamin P. Levy, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC
John O. Mascarenhas, MD
Director, Center of Excellence in Blood Cancers and Myeloid Disorders
Professor of Medicine
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, NY
Tiffany A. Traina, MD, FASCO
Associate Attending Physician
Vice Chair, Oncology; Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine, Weill Cornell Medicine
New York, NY
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of
Registered Nursing, Provider #16669, for 18.0 Contact Hours (Day 1=6.5; Day
2=5.5; Day 3=6.0).
Physicians
Education Resource®, LLC is accredited by the Accreditation Council for
Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This
knowledge-based activity is approved for a maximum of 18.0 contact hours
(18.0 CEUs) under several UAN numbers.
Medical Oncologists (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note: The CE credit/MOC point amounts above include credits/points for
the main session presentations and the Spotlight CE Sessions.
There are several opportunities (both continuing education [CE] and non-CE) available for companies, associations, and societies interested in supporting this year's conference.
For Continuing Education, Associations, and Societies
Please email grants@gotoper.com for information about this upcoming conference.
Exhibitors
Exhibit at this year’s meeting and increase your visibility. Our custom sponsorship packages provide outstanding recognition and increased awareness of your company’s products and services. Don’t miss this opportunity to reach this important target audience.
For additional details, contact:
Elisha Ball | Associate Director of Sales
OncLive® Events & Intellisphere Oncology Specialty Group
Cell: (610) 563-1620
Email: egarcia@onclive.com
Maddison Martini | National Accounts Associate
OncLive® Events & Intellisphere Oncology Specialty Group
Cell: (609) 947-8377
Email: mmartini@mjhlifesciences.com
OncLive® Events & Intellisphere Oncology Specialty Group
259 Prospect Plains Rd, Building H, Monroe, NJ 08831
Web: http://www.onclive.com
Advisory Board or Ancillary Meeting Definition
Any meeting whose invited participants are professional attendees of the Conference, such as doctors and physicians will be considered an Advisory Board (Ad Board) or Ancillary Meeting. This includes activities such as round-table discussions, investigator meetings, social gatherings and meet the specialist‐type meetings.
A fee is applicable for hosting these meetings, with the amount being dependent on the type and size of your meeting.
Blackout Times
There are many programs being scheduled throughout our conferences. With that, the black out hours across our meeting are as follows:
- One day prior to the conferences
- The duration of the conference
- One day post conference
To review your meeting request, please contact Elisha Ball or Maddison Martini.
A cancellation fee of 25% will be assessed on refunds requested 90 days before the start date, a 50% fee on refunds requested 60 days before the start date, and a 75% fee on refunds requested 30 days before the start date. No refunds will be made after 30 days before the start date. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.
In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.
PER® reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting continuing education materials.